High expression of the immature laminin receptor protein correlates with mutated IGVH status and predicts a favorable prognosis in chronic lymphocytic leukemia

Leukemia Research

Volumn 35, Issue 6, 2011, Pages 721-729

  Friedrichs Birte, B ^a,b   Siegel, Sandra ^a   Reimer, Rudolph ^c   Barsoum, Adel ^d   Coggin, Joseph ^d   Kabelitz, Dieter ^e   Heidorn, Klaus ^f   Schulte, Christoph ^f   Schmitz, Norbert ^a   Zeis, Matthias ^a  

^a DEPARTMENT OF CARDIOLOGY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

^d UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF KIEL   (Germany)

^f Institute of Hematopathology Hamburg   (Germany)

Author keywords

Chronic lymphocytic leukemia; IGVH mutational status; Immature laminin receptor; Prognosis; Tumor antigen

Indexed keywords

CD38 ANTIGEN; IMMATURE LAMININ RECEPTOR; IMMUNOGLOBULIN HEAVY CHAIN; LAMININ RECEPTOR; PROTEIN KINASE ZAP 70; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL STIMULATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN HEAVY CHAIN GENE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD38; BLOTTING, WESTERN; CELLS, CULTURED; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, LAMININ; RIBOSOMAL PROTEINS; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 79955586160     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.10.002     Document Type: Article

References (33)

1. Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Dohner H., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008, 111:5446-5456.
2. Binet J.L., Auquier A., Dighiero G., Chastang C., Piguet H., Goasuen J., et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981, 48:198-206.
3. Rai K.R., Sawitsky A., Cronkite E.P., Chanana A.D., Levy R.N., Pasternack B.S. Clinical staging of chronic lymphocytic leukemia. Blood 1975, 46:219-234.
4. Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94:1840-1847.
5. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., Stevenson F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848-1854.
6. Oscier D.G., Gardiner A.C., Mould S.J., Glide S., Davis Z.A., Ibbotson R.E., et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002, 100:1177-1184.
7. Krober A., Seller T., Benner A., Bullinger L., Brückle E., Lichter P., et al. VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002, 100:1410-1416.
8. Rassenti L.Z., Huynh L., Toy T.L., Chen L., Keating M.J., Gribben J.G., et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004, 351:893-901.
9. Crespo M., Bosch F., Villamor N., Bellosillo B., Colomer D., Rozman M., et al. ZAP-70 expression as a surrogate marker for immunoglobuline-variable region mutations in chronic lymphocytic leukemia. N Engl J Med 2003, 348:1764-1775.
10. Wiestner A., Rosenwald A., Barry T.S., Wright G., Davis R.E., Henrickson S.E., et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003, 101:4944-4951.
11. Letestu R., Rawstron A., Ghia P., Villamor N., Boeckx N., Boettcher S., et al. Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: a multicentric international harmonization process. Cytometry B: Clin Cytometry 2006, 70:309-314.
12. Nolz J.C., Tschumper R.C., Pittner B.T., Darce J.R., Kay N.E., Jelinek D.F. Zap-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype. Leukemia 2005, 19:1018-1024.
13. Cutrona G., Colombo M., Matis S., Reverberi D., Dono M., Tarantino V., et al. B lymphocytes in humans express Zap-70 when activated in vivo. Eur J Immunol 2006, 36:558-569.
14. Scielzo C., Camporeale A., Geuna M., Alessio M., Poggi A., Zocchi M.R., et al. Zap-70 is expressed by normal and malignant human B-cell subsets of different maturational stage. Leukemia 2006, 20:589-595.
15. Ibrahim S., Keating M., Do K.A., O'Brien S., Huh Y.O., Jilani I., et al. CD38 expression as an important prognostic factor in B cell chronic lymphocytic leukemia. Blood 2001, 98:181-186.
16. Hamblin T.J., Orchard J.A., Ibbotson R.E., Davis Z., Thomas P.W., Stevenson F.K., et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002, 99:1023-1029.
17. Siegel S., Wagner A., Kabelitz D., Marget M., Coggin J., Barsoum A., et al. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies. Blood 2003, 102:4416-4423.
18. Castronovo V. Laminin receptors and laminin-binding proteins during tumor invasion and metastasis. Invas Metastat 1993, 13:1-30.
19. Coggin J.H., Barsoum A.L., Rohrer J.W. Tumors express both unique TSTA and crossprotective 44kDa oncofetal antigen. Immunol Today 1998, 19:405-408.
20. Muller-Hermelink H.K., Montserrat E., Catovsky D., Campo E., Harris N.L., Stein H. Chronic lymphocytic leukemia/small lymphocytic lymphoma. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues 2008, 180-182. IARC Press, Lyon. S.H. Swerdlow, E. Campo, N.L. Harris, E. Jaffe, S.A. Pileri, H. Stein (Eds.).
21. Dohner H., Stilgenbauer S., Fischer K., Bentz M., Lichter P. Cytogenetic and molecular cytogenetic analysis of B cell chronic lymphocytic leukemia: specific subgroups of patients and point of loci of candidate genes. Leukemia 1997, 11:19-24.
22. Ritgen M., Stilgenbauer S., von Neuhoff N., Humpe A., Brüggemann M., Pott C., et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 2004, 104:2600-2602.
23. Von Bergwelt-Baildon M.S., Vonderheide R.H., Maecker B., Hirano N., Anderson K.S., Butler M.O., et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 2002, 99:3319-3325.
24. Liang H., Nishioka Y., Reich C.F., Pisetsky D.S., Lipsky P. Activation of human B cells by phospho-rothioate oligonucleotides. J Clin Invest 1996, 98:1119-1129.
25. Bauer M., Wagner H., Heeg K., Lipford G.B. DNA activates human immune cells through a CpG sequence-dependent manner. Immunology 1999, 97:699-705.
26. Chen L., Widhopf G., Huynh L., Rassenti L., Rai K.R., Weiss A., et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002, 100:4609-4614.
27. Cochran D.A., Evans C.A., Blinco D., Burthem J., Stevenson F.K., Gaskell S.J., et al. Proteomic analysis of chronic lymphocytic leukemia subtypes with mutated or unmutated Ig V(H) genes. Mol Cell Proteomics 2003, 12:1331-1341.
28. Castronovo V., Taraboletti G., Sobel M.E. Functional domains of the 67-kDa laminin receptor precursor. J Biol Chem 1991, 266:2040-2046.
29. Salama R.H., Muramatsu H., Zou K., Inui T., KimuraT, Muramatsu T. Midkine binds to 37-kDa laminin binding protein precursor, leading to nuclear transport of the complex. Exp Cell Res 2001, 270:13-20.
30. Rohrer J.W., Coggin J.H. CD8 T cell clones inhibit antitumor T cell function by secreting IL-10. J Immunol 1995, 155:5719-5723.
31. Holtl L., Zelle-Rieser C., Gander H., Papesh C., Ramoner R., Bartsch G., et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 2002, 8:3369-3376.
32. Siegel S., Wagner A., Friedrichs B., Wendeler A., Wendel L., Kabelitz D., et al. Identification of HLA-A*0201-presented T cell epitopes derives from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies. J Immunol 2006, 47:978-985.
33. Friedrichs B., Siegel S., Kloess M., Barsoum A., Coggin J., Rohrer J., et al. Humoral immune responses against the immature laminin receptor protein show prognostic significance in patients with chronic lymphocytic leukemia. J Immunol 2008, 180:6374-6384.